Prior irinotecan hypersensitivity or toxicity that would suggest an inability to tolerate irinotecan 180 mg/m2 every 2 weeks
Irinotecan, temozolomide and mammalian target of rapamycin (mTOR) inhibitor exposure:\r\n* Patients who have received prior single agent therapy with irinotecan, temozolomide, or an mTOR inhibitor, excluding ABI-009, are eligible\r\n* Patients who have received prior therapy with ABI-009 are not eligible\r\n* Patients who have previously received irinotecan and temozolomide in combination without progressive disease while on therapy are eligible\r\n* Patients who have previously received irinotecan and temozolomide in combination and had significant toxicity with these two drugs are not eligible\r\n* Patients who have received prior therapy with all three agents in combination (i.e. irinotecan, temozolomide, and an mTOR inhibitor) are not eligible
Known hypersensitivity to irinotecan
Patients previously treated with irinotecan are eligible for this study
Prior therapy with irinotecan (for expansion phase II only)
Documented progression on and/or intolerance/hypersensitivity to both paclitaxel and irinotecan (Part B only)
irinotecan,
Any history of hypersensitivity to irinotecan
Prior treatment with PM01183, trabectedin (Yondelis®) or topoisomerase I inhibitors (irinotecan, topotecan, etc.).
Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .
No history of severe reactions to fluorouracil (5-FU), irinotecan hydrochloride (irinotecan), or a monoclonal antibody
Patients who have required toxicity related dose reductions of greater than 50% of the original dose of infusional 5-FU and/or irinotecan during the administration of FOLFIRI/bevacizumab
Phase 2: Received prior therapies with eribulin mesilate or irinotecan.
Prior treatment with irinotecan or temozolomide is permitted
Patients with a history of an anaphylactic reaction to irinotecan.
Prior treatment with a Wee1 inhibitor or any irinotecan containing regimen
History of hypersensitivity to AZD1775, irinotecan, or any excipients of these agents
Patients must be irinotecan refractory; patients must have progressed on prior irinotecan therapy but must be able to tolerate standard irinotecan doses
No prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride), fluorouracil or capecitabine
History of hypersensitivity reactions to products containing irinotecan (irinotecan), topotecan or other topoisomerase inhibitors, gadolinium contrast agents or lipid products
Prior treatment with irinotecan and/or bevacizumab
Previously treated with at least one prior irinotecan-containing regimen for colorectal cancer.
Previously treated with at least one prior irinotecan-containing regimen for colorectal cancer
Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I inhibitors.
Patients who have severe hypersensitivity to irinotecan hydrochloride (HCl)
Patients must not have received prior irinotecan-based chemotherapy (e.g. irinotecan hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin [FOLFIRINOX] or FOLFIRI)
Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin
Patients must not have had any prior treatment with oxaliplatin or irinotecan hydrochloride (irinotecan) within 3 years prior to registration; patients must not have had prior chemotherapy in metastatic setting; prior abdominal radiation therapy is not allowed
History of allergic reactions attributed to the following: \r\n* Camptothecin derivatives (e.g., topotecan [topotecan hydrochloride], irinotecan, or exatecan [exatecan mesylate]) \r\n* Any ingredients contained within the liquid irinotecan solution (e.g., sorbitol) or\r\n* Any antiemetics or antidiarrheals appropriate for administration with study therapy (e.g., loperamide or dexamethasone)
Known hypersensitivity to irinotecan
Prior irinotecan treatment
Taking any other systemic anticancer agent (docetaxel, doxorubicin, irinotecan)
Patients previously treated with irinotecan-containing regimen
Hypersensitivity to 5FU (fluorouracil), oxaliplatin (or other platinum agents), irinotecan (irinotecan hydrochloride) (or to their excipients)
Prior treatment with irinotecan, topotecan, or dinutuximab.
Previous failure of at least one fluoropyrimidine- and irinotecan-containing chemotherapy regimen for metastatic disease; Note: previous failure is defined as disease progression while receiving treatment or within 6 weeks after the last dose of irinotecan; failure for this assessment is defined as any enlargement of measurable or assessable lesion(s) or the development of any new lesion; a rising tumor marker alone is not sufficient to define failure; patients can have received irinotecan in any previous line of therapy
Prior intolerance to irinotecan and/or bevacizumab despite dose reduction
Subject must have received at least oxaliplatin-, and irinotecan-based regimens with bevacizumab and with, cetuximab or panitumumab if KRAS wildtype and are refractory to irinotecan;
Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.
For patients to be treated with a regimen containing irinotecan:
Known hypersensitivity to irinotecan
Prior treatment with a topoisomerase I inhibitor (i.e. irinotecan, topotecan)
Has a previous treatment with irinotecan
Any prior therapy with irinotecan
Prior treatment with a topoisomerase-I inhibitor (e.g., topotecan, irinotecan)
Prior intolerance of irinotecan or necessity for dose reduction greater than 20%
Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
Participants may not have received any prior camptothecin, including but not limited to: topotecan, irinotecan
Prior irinotecan treatment.
History of intolerance to irinotecan at dose-intensity of 125 mg/m^2/2 weeks or lower
Progression on irinotecan containing regimen
Patients may not previously have received irinotecan, topotecan or other topoisomerase I inhibitor
Progression of disease after at least one prior standard of care regimen or intolerant to irinotecan based regimens
- irinotecan
14 days from administration of vincristine or irinotecan